Biotest (BIO3) AI Stock Analysis

• Market Cap: €1.42B
• Dividend Yield: 0.13%
• Average Volume (3M): 861.00
• Price to Earnings (P/E): 45.0
• Beta (1Y): -0.03
• Revenue Growth: -18.82%
• EPS Growth: -113.85%
• Country: DE
• Employees: 2,495
• Sector: Healthcare
• Sector Strength: 37
• Industry: Biotechnology
• EPS (TTM): N/A
• Shares Outstanding: 19,785,727
• 10 Day Avg. Volume: 834
• 30 Day Avg. Volume: 861
• PEG Ratio: N/A
• Price to Book (P/B): 0.00
• Price to Sales (P/S): 0.00
• P/FCF Ratio: 0.00
• Enterprise Value/Market Cap: N/A
• Enterprise Value/Revenue: N/A
• Enterprise Value/Gross Profit: N/A
• Enterprise Value/Ebitda: N/A
• 1Y Price Target: €31.00
• Price Target Upside: 2.65% Upside
• Rating Consensus: Hold
• Number of Analyst Covering: 0

• Rating: 60 Neutral
• Price Target: €31.00 ▲(2.65% Upside)

The most significant factor influencing the overall score is the financial performance, with revenue growth and operational efficiency improvements offset by concerns over profitability and leverage. Technical analysis indicates neutral market momentum, while valuation is challenged by a negative P/E ratio. The lack of earnings call data and corporate events means these factors do not influence the score.

Biotest Business Overview & Revenue Model

Company Description

Biotest AG is a global biotechnology company located in Germany, specializing in the development, production, and distribution of biological products with applications in hematology, clinical immunology, and intensive care medicine. The company's core products include plasma protein therapies such as immunoglobulins, clotting factors, and albumins derived from human blood plasma. Biotest is committed to advancing healthcare through innovative therapies that address critical medical needs.

How the Company Makes Money

Biotest generates revenue primarily through the sale of its plasma protein products, which are used to treat various medical conditions such as immune deficiencies, bleeding disorders, and critical care situations. The company collects human plasma through its network of plasma donation centers, processes it into therapeutic products, and distributes these products to healthcare providers globally. Key revenue streams include direct sales to hospitals and clinics, partnerships with pharmaceutical companies for product distribution, and licensing agreements. Biotest's earnings are influenced by factors such as demand for plasma-derived therapies, regulatory approvals, and its ability to maintain a reliable and efficient plasma collection and production infrastructure.

Biotest Financial Statement Overview

Summary

Biotest has shown revenue growth and improved operational efficiency. However, a decline in net profit margin and increased leverage are concerning. While cash flows have improved, cash conversion efficiency remains a challenge. The overall financial health is stable but with risks.

Income Statement

Biotest has shown a positive revenue growth from 2019 to 2024 with a compound annual growth rate. The gross profit margin improved significantly from the previous years but remains moderate. However, the net profit margin has fallen drastically in 2024 compared to 2023, indicating decreased profitability. The EBIT and EBITDA margins have shown improvement over the years, indicating better operational efficiency.

Balance Sheet

The debt-to-equity ratio has increased, indicating higher leverage, which could pose financial risk. The return on equity (ROE) declined in 2024 due to lower net income. The equity ratio has improved modestly, reflecting a stable capital structure.

Cash Flow

Free cash flow turned positive in 2024, showing improvement in cash management. However, the operating cash flow to net income ratio is low, indicating potential issues with cash conversion. The free cash flow to net income ratio has improved but still reflects challenges in converting income into cash.

Breakdown	Dec 2024	Dec 2023	Dec 2022	Dec 2021	Dec 2020
Income Statement
Total Revenue	726.20M	684.60M	516.10M	515.60M	484.20M
Gross Profit	223.80M	280.30M	124.90M	80.70M	130.10M
EBITDA	120.40M	179.00M	28.30M	-17.70M	16.00M
Net Income	26.40M	127.00M	-31.60M	-63.30M	-31.40M
Balance Sheet
Total Assets	1.43B	1.41B	1.20B	1.10B	1.13B
Cash, Cash Equivalents and Short-Term Investments	119.50M	118.50M	136.60M	117.50M	89.20M
Total Debt	597.20M	689.80M	574.30M	496.30M	469.10M
Total Liabilities	903.30M	912.00M	831.90M	723.80M	689.70M
Stockholders Equity	530.70M	498.90M	371.10M	380.40M	441.60M
Cash Flow
Free Cash Flow	32.20M	-36.10M	-69.80M	15.70M	-43.70M
Operating Cash Flow	60.90M	-2.70M	-40.50M	33.90M	-16.70M
Investing Cash Flow	-25.70M	1.30M	-37.00M	-23.40M	-14.60M
Financing Cash Flow	-35.40M	-6.80M	89.60M	22.60M	42.00M

Biotest Technical Analysis

• Technical Analysis Sentiment: Positive
• Last Price: 30.20
• 50DMA: Positive
• 100DMA: Positive
• 200DMA: Positive
• MACD: Negative
• RSI: Neutral
• STOCH: Negative

Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For DE:BIO3, the sentiment is Positive. The current price of 30.2 is above the 20-day moving average (MA) of 29.51, above the 50-day MA of 29.62, and above the 200-day MA of 28.63, indicating a bullish trend. The MACD of 0.12 indicates Negative momentum. The RSI at 54.84 is Neutral, neither overbought nor oversold. The STOCH value of 100.00 is Negative, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Positive sentiment for DE:BIO3.

Biotest Peers Comparison

Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
ILM1	76 Outperform	$330.04M	21.94	2.99%	―	5.62%	-21.87%
DMP	66 Neutral	€1.74B	16.76	16.97%	2.79%	6.24%	83.05%
Sector *	63 Neutral	€5.95B	18.53	-1.87%	2.14%	0.64%	-40.16%
BIO3	60 Neutral	€1.42B	44.96	-4.72%	0.13%	-18.82%	-113.85%
EUZ	60 Neutral	€3.72B	33.62	17.48%	0.77%	9.42%	8.99%
FYB	57 Neutral	€455.83M	5.89	-26.06%	―	-10.32%	-250.76%
EVT	45 Neutral	€1.20B	―	-20.51%	―	1.50%	-127.76%